Protocol Number: CLIN-Protocol-0046
Sponsor: Ocular Therapeutix
Information: A phase 1 open-label, dose escalation study of OTX-TKI (axitinib implant) for intravitreal use in subjects with neovascular age-related macular degeneration
For the health and safety of our patients, staff and visitors, we ask you do not enter the QEI South Brisbane or QEI Clayfield facilities if you:
Please note that all visitors at this time will undergo contactless temperature checking. Our staff will also require the full names and contact details of all visitors to the building.
Thank you for your cooperation at this time, please don't hesitate to contact us on 07 3239 5000 if you have any concerns.